Turner Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Turner Investments’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,500	Closed	-$176K	–	260
2016 Q4	$176K	Buy	+2,500	New	+$177K	0.07%	231
2015 Q2	–	Sell	-10,000	Closed	-$621K	–	359
2015 Q1	$621K	Buy	+10,000	New	+$555K	0.11%	207

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Turner Investments's RARE Position: Q1 2017 in Review

Turner Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 2,500 shares — an estimated $176K sold.

Turner Investments first reported a position in RARE in Q1 2015 and held it in 2 quarters. The position peaked at $621K in Q1 2015. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

Turner Investments reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
Turner Investments sold 2,500 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $176K.
Turner Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 2 quarters.
Turner Investments's Ultragenyx Pharmaceutical position peaked at $621K in Q1 2015.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.